HomeCompareVECT vs PLD

VECT vs PLD: Dividend Comparison 2026

VECT yields 11.86% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PLD wins by $6.46M in total portfolio value· pulled ahead in Year 4
10 years
VECT
VECT
● Live price
11.86%
Share price
$16.87
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$43.7K
Annual income
$2,485.28
Full VECT calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — VECT vs PLD

📍 PLD pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVECTPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VECT + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VECT pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VECT
Annual income on $10K today (after 15% tax)
$1,007.71/yr
After 10yr DRIP, annual income (after tax)
$2,112.49/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, PLD beats the other by $4,465,858.27/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VECT + PLD for your $10,000?

VECT: 50%PLD: 50%
100% PLD50/50100% VECT
Portfolio after 10yr
$3.27M
Annual income
$2,629,460.73/yr
Blended yield
80.31%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

VECT
Analyst Ratings
3
Buy
Consensus: Buy
Price Target
$18.00
+6.7% upside vs current
Range: $18.00 — $18.00
Altman Z
13.9
Piotroski
4/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VECT buys
0
PLD buys
0
No recent congressional trades found for VECT or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVECTPLD
Forward yield11.86%3.18%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$43.7K$6.50M
Annual income after 10y$2,485.28$5,256,436.18
Total dividends collected$18.2K$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$18.00$136.00

Year-by-year: VECT vs PLD ($10,000, DRIP)

YearVECT PortfolioVECT Income/yrPLD PortfolioPLD Income/yrGap
1$11,886$1,185.54$11,255$555.24+$631.00VECT
2$14,034$1,316.89$13,062$1,018.59+$972.00VECT
3$16,470$1,453.25$15,903$1,926.67+$567.00VECT
4← crossover$19,217$1,593.89$20,839$3,823.32$1.6KPLD
5$22,300$1,738.05$30,464$8,166.08$8.2KPLD
6$25,746$1,884.96$52,054$19,457.30$26.3KPLD
7$29,582$2,033.87$109,886$54,188.93$80.3KPLD
8$33,837$2,184.03$304,030$186,451.18$270.2KPLD
9$38,540$2,334.73$1,166,125$840,813.32$1.13MPLD
10$43,723$2,485.28$6,504,190$5,256,436.18$6.46MPLD

VECT vs PLD: Complete Analysis 2026

VECTStock

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). The company was incorporated in 2019 and is headquartered in Basel, Switzerland.

Full VECT Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this VECT vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VECT vs SCHDVECT vs JEPIVECT vs OVECT vs KOVECT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.